AstraZeneca chief is betting the company’s future on a single roll of the dice
The view from Endpoints
Nearly five years into his stint at the helm of AstraZeneca, CEO Pascal Soriot has now reached his year of living dangerously.
This morning the pharma chief outlined a steadily declining rate of revenue. Core EPS is expected to slide in the low to mid teens as generics continue to chop away at their Crestor franchise. All their old blockbusters are being disenfranchised, in a manner of speaking.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.